Instituto Quimioterapeutico
Business Opportunity Assessment Report

Company Snapshot

Instituto Quimioterapéutico S.A. (IQFARMA) is a Peruvian pharmaceutical procurement and distribution entity headquartered in Lima, operating as a key buyer in Peru’s health sector supply chain. Its core function centers on sourcing active pharmaceutical ingredients (APIs), chemical intermediates, and lab/production equipment—evidenced by dominant HS codes 2941909000 (other heterocyclic compounds) and 8422900000 (parts of packaging machinery). Structurally, it exhibits high transaction frequency (4,276+ recorded shipments over 3 years) with pronounced concentration in U.S.-origin cargo via Miami port (38.2% of all shipments). A notable surge occurred in Q1 2025, with transaction volume peaking at 4.32M units in April 2024 — suggesting accelerated operational scaling or new contract execution.

Company Attribute Information

Trade Trend Analysis

Data解读: Transaction volume shows extreme volatility — two massive spikes (April 2024: 4.32M units; June 2025: 2.05M units) account for ~45% of total 3-year volume, while 12 months show sub-50K units. This bimodal pattern indicates project-driven procurement cycles rather than steady commercial replenishment. The 2026 rebound (Jan–May averaging 115K units/month) signals sustained operational activity post-spike normalization. Risk-wise, reliance on episodic large orders increases forecasting uncertainty and exposes supply continuity to single-contract dependency.

Trade Partner Analysis

Data解读: Top partners are globally dispersed but heavily weighted toward specialized pharmaceutical equipment suppliers (Uhlmann PAC Systems, Romaco Tecpharm) and regulatory/compliance entities (US Pharmacopeia Convention). Peru-based partners dominate by count (427 transactions), yet non-Peruvian suppliers contribute 76.1% of total transaction volume — confirming IQFARMA’s role as an international procurement hub serving domestic end-users. Notably, 6 of top 20 partners are newly added since 2025 (e.g., Uhlmann Pac Systems GmbH & Co. KG, Dangschat Toh GmbH), reflecting strategic supplier diversification. This partner mix signals strong alignment with GMP-compliant infrastructure development — but also reveals vulnerability to geopolitical shifts affecting Russian and German suppliers.

HS Code Analysis

Data解读: HS coding reveals a dual-core procurement profile: 57% of transactions (1,211/2,124) fall under organic chemical categories (HS 29xxxx series), particularly APIs and heterocyclic compounds (2941909000, 2934999000), while 22% cover machinery parts (8422900000, 8479900000) — strongly indicating parallel investment in both raw material supply and production line modernization. Notably, no finished dosage forms (e.g., HS 3004) appear in top 20, confirming IQFARMA does not engage in final drug manufacturing. This clear demarcation between chemical inputs and capital equipment signals long-term capacity-building intent — but excludes opportunities in branded finished pharmaceuticals.

Trade Region Analysis

Data解读: Procurement geography is highly diversified across 20 countries, yet dominated by three strategic corridors: North America (USA + Costa Rica = 32% of transactions), Asia (India + China = 18.0%), and Western Europe (Spain + Germany + France = 19.1%). The 'Other' category (24.0%) — likely representing consolidated shipments via global logistics hubs — further confirms IQFARMA’s reliance on third-party freight consolidation. Strong representation from Latin American nations (Costa Rica, Colombia, Panama) suggests regional supply chain integration efforts. This multi-regional strategy enhances resilience but complicates compliance harmonization across varying pharmacopeial standards (USP vs. Ph. Eur. vs. IP).

Export Port Analysis

Data解读: Miami port dominates inbound logistics (38.2% of all shipments), functioning as the primary gateway for U.S.-sourced goods and transshipment hub for Latin American deliveries. Shanghai (11.8%) and Barcelona (5.3%) serve as secondary gateways for Asian and European supply — consistent with HS code evidence of machinery and API imports. Notably, Indian ports (Nhava Sheva, Mumbai) collectively represent 6.7% of entries, aligning with strong trade ties to Indian API suppliers. The presence of niche ports like Strasbourg and Laupheim reflects specialized high-value shipments (e.g., analytical instruments, GMP-certified components). Over-reliance on Miami creates single-point-of-failure risk — especially given U.S. CBP scrutiny on pharmaceutical imports and potential port congestion.

Contact Information

• Official Website: Not publicly verifiable (no active domain found in search results)
• LinkedIn: Not identified (no verified corporate page)
• Email: Not disclosed in public sources
• Phone: Not disclosed in public sources
• Address: Av. Santa Rosa 350, Santa Anita, Lima, Peru

Company Trade Summary

• IQFARMA functions as a regulated pharmaceutical distributor focused on API and chemical intermediate procurement — not finished drug marketing.
• It operates a globally diversified but operationally concentrated supply chain, anchored by Miami port and U.S./Indian/European suppliers.
• Procurement behavior reflects infrastructure investment: machinery parts (HS 8422/8479) and GMP-aligned chemicals (HS 293x/294x) dominate — signaling production capability upgrades.
• High volatility in order volume implies project-based demand — requiring flexible, scalable supply partnerships.
• Absence of official digital footprint (no website, LinkedIn, or contact data) limits direct outreach — channel partners or regulatory intermediaries are recommended entry points.